Company Revenue

The company captured market share in 2022, growing more than 24% through new product introductions and expanded distribution....

The company declined in the mid-teens during 2022 as it exits markets, fills portfolio gaps and modernizes its operations....

The company grew 23% in 2022, its first year as a publicly traded company. New products and sales force expansion...

The company grew more than 44% in 2022 through its sole focus on spine surgery. ATEC expects to grow another...

The company's product revenue declined in the low single digits in 2022 as it transforms its business model and contends...

The company grew 18% in 2022, driven by accelerating demand momentum in its core SI-fusion business and increased surgeon engagement....

The company's MACI sales grew more than 18% for FY22 and greatly accelerated its path toward a new arthroscopic delivery...

Enovis reported 4Q22 orthopedic sales of $162.5 million, +10.4% compared to 4Q21. Including contributions from acquisitions, the company generated $599.4...

The company's reported orthopedic sales grew by low-single digits during the third quarter of its 2023 fiscal year....

The company exited 2022 with mid-single digit growth despite macro headwinds, driven by its C360 portfolio and international sales....